REPLIGEN CORP
Customers
1
0 disclosed
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Latest period
Mar 31, 2023
10-Q filed 2024-05-01
Customers 1
Companies RGEN discloses as major customers, as a share of RGEN revenue. 0 active, 1 lapsed.
| Company | % of RGEN revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| PFE PFIZER INC |
11% | $18.2M | 3M 2023-03-31 | +1.0pp | Lapsed Last seen 2023-03-31 |
10-Q 2024-05-01 |
Revenue from sales to Pfizer, Inc. were $20.1 million, or 11.0% of the Company's total revenue for the three months ended March 31, 2023. Revenue from Pfizer Inc. accounted for 10% of total revenue for the year ended December 31, 2021, and MilliporeSigma accounted for 11% of total revenues in the year ended December 31, 2020.Significant accounts receivable balances representing 10% or more of the Company’s total trade accounts receivable balances at December 31, 2022 and 2021 is as follows: December 31, December 31, 2022 2021 Purolite (an Ecolab Inc. company) 13 % N/A Pfizer Inc. N/A 14 % 80 Business Combinations, Goodwill and Intangible Assets Business Combinations Total consideration transferred for acquisitions is allocated to the tangible and intangible assets acquired and liabilities assumed, if any, based on their fair values at the dates of acquisition. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition.Revenue from customers that represented 10% or more of the Company's total revenue for the periods presented in our consolidated statements of comprehensive income came from sales to Pfizer Inc. during the three months ended September 30, 2021 only, which generated $19.1 million, or 11% of the Company's total revenue for the period. Revenue from sales to Pfizer, Inc. was $21.1 million, or 10.2% of the Company's total revenue for the three months ended March 31, 2022. Revenue from Pfizer Inc. accounted for 10% of total revenue for the year ended December 31, 2021. Revenue from Pfizer Inc. accounted for 10% of total revenue for the year ended December 31, 2021, and MilliporeSigma accounted for 11% of total revenues in the year ended December 31, 2020. Revenue from customers that represented 10% or more of the Company’s total revenue for the three months ended September 30, 2021 and 2020 came from sales to Pfizer Inc. during the three months ended September 30, 2021, which generated $19.1 million, or 11% of the Company's total revenue for the period. | ||||||
Unnamed major customers
Disclosed without names in the fiscal year ending 2019-12-31. Identities are not inferred.
Alerts are coming
Get an email when RGEN's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.